Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amrita Krishnan

Showing results (51-60 of 114) with videos related to

Pageof 12
Sort By:
Clinical Pharmacology and Therapeutics|July 24, 2025
Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology ResultsJue Gong, Jie Zhou, Dongfen Yuan, et al.
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Journal of Comparative Effectiveness Research|April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myelomaAmrita Krishnan, Ajay K Nooka, Ajai Chari, et al.
Leukemia|February 22, 2020
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myelomaAmrita Krishnan, Prashant Kapoor, Joycelynne M Palmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2019
Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell TransplantationThomas P Slavin, Jennifer Berano Teh, Jeffrey N Weitzel, et al.
Oncoimmunology|October 6, 2018
Daratumumab induces CD38 internalization and impairs myeloma cell adhesionJayeeta Ghose, Domenico Viola, Cesar Terrazas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 24, 2018
Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow TransplantationSita Bhella, Navneet S Majhail, Jeffrey Betcher, et al.
Pageof 12

Showing results (51-60 of 114) with videos related to

Sort By:
Pageof 12
Clinical Pharmacology and Therapeutics|July 24, 2025
Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology ResultsJue Gong, Jie Zhou, Dongfen Yuan, et al.
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Journal of Comparative Effectiveness Research|April 28, 2023
Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myelomaAmrita Krishnan, Ajay K Nooka, Ajai Chari, et al.
Leukemia|February 22, 2020
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myelomaAmrita Krishnan, Prashant Kapoor, Joycelynne M Palmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2019
Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell TransplantationThomas P Slavin, Jennifer Berano Teh, Jeffrey N Weitzel, et al.
Oncoimmunology|October 6, 2018
Daratumumab induces CD38 internalization and impairs myeloma cell adhesionJayeeta Ghose, Domenico Viola, Cesar Terrazas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 9, 2018
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, J Christine Ye, Alan Howard, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 24, 2018
Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow TransplantationSita Bhella, Navneet S Majhail, Jeffrey Betcher, et al.
Pageof 12